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Abstract
Background—Current capsule endoscopy (CE) provides minimally invasive technology for
gastrointestinal imaging, but has limited ability to discriminate different polyp types. Near Infrared
Fluorescent (NIRF) probes activated by biomarkers upregulated in adenomas (e.g., cathepsin B) are
potentially powerful tools to distinguish premalignant or malignant lesions from benign or
inflammatory lesions.
Objectives—To examine whether CE can be integrated with NIRF probes to detect adenomas, and
whether cathepsin B activated NIRF probes are activated by benign or inflammatory ones.
Design and Setting—Mouse models of adenomas, hyperplastic/lymphoid polyps, and acute or
chronic intestinal inflammation were injected intravenously with a cathepsin B activated probe
(Prosense™ 680). Dissected intestine was imaged with CE under white or NIRF light. For NIRF,
excitation (680 nm), dichroic and emission (700 nm) filters were combined with CE when images
were recorded. Prosense™ 680 samples with or without protease were used as positive and negative
controls. CE based imaging data was verified using an independent imaging system (Xenogen IVIS
system).
Main Outcome Measurements—Proof of principle that CE integrated with NIRF probes can
detect and discriminate adenomas from other lesions.
Results—CE based NIRF imaging with Prosense™ 680 readily visualized adenomas, including in
the colitis model. NIRF signals of different intensities were detected. Prosense™ 680 was not
activated by benign or inflammatory lesions.
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Limitations—Optical filters external to capsule were used.
Conclusions—We demonstrate proof of principle of biochromoendoscopy, CE combined with
molecular probes, provides a novel approach that differentiates adenomas from benign polyps and
inflammatory lesions.
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INTRODUCTION
Early detection of premalignant and malignant lesions is crucial for the prevention and
treatment of gastrointestinal cancers. With the advent of fiberoptic endoscopy, lesions of the
upper gastrointestinal (GI) tract and colon can be readily detected. However, the majority of
the small intestine remains inaccessible with conventional endoscopy. As with all invasive
procedures, fiberoptic endoscopy has finite risks including bleeding, perforation and sedation-
associated cardiopulmonary complications.
Capsule endoscopy (CE) is a minimally invasive technology which was originally designed to
provide diagnostic imaging of the entire small intestine1, 2. The commercially available
endoscopic capsule is composed of a lens, light-emitting diodes (LEDs), digital imager (CMOS
chip), battery, and transmitter. Once the capsule is swallowed, white light images are captured
and transmitted to a recorder via sensor arrays fastened to the abdomen. Data collected in the
recorder can then be downloaded and analyzed as a video. Current indications for CE are
evolving and include obscure gastrointestinal hemorrhage, Crohn’s disease, and the diagnosis
of small bowel polyps or tumors3. There is increasing interest in the use of CE for detection
of pathology in esophagus, stomach and colon4-6. However, CE cannot readily classify
abnormalities as malignant (adenocarcinoma), premalignant (adenoma), or benign
(hyperplastic, lymphoid).
Certain molecular biomarkers, including proteases such as cathepsin B, are up regulated in
neoplastic lesions7. Synthetic probes activated by these biomarkers, termed “molecular
beacons”, may be valuable tools for detecting premalignant and malignant lesions8-11. These
probes are intravenously administered and are essentially undetectable in tissues unless locally
activated by enzymes that specifically cleave and activate the probe, causing the probe to emit
near infrared fluorescence (NIRF)12, 13. ApcMin/+ mice are a model of adenomatous polyposis
of small intestine and colon. In this model, a cathepsin B activatable NIRF probe has been
shown to be highly sensitive in the detection of even small adenomas, and to distinguish
neoplastic lesions from normal mucosa with high specificity9. Prior studies using this probe
detected the emitted NIRF by conventional fluorescence microscopy9 or by a real-time animal
model endoscope equipped with modified near infrared light source, appropriate filters and a
charge-coupled device (CCD) camera14. Like conventional fiberoptic endoscopy, the use of
fiberoptic endoscopy in combination with molecular probes is invasive. The potential for
distinguishing premalignant lesions from benign polyps and inflammatory lesions using this
imaging technology has not been reported.
In our study, we aimed to provide proof of principle that biochromoendoscopy, which combines
CE and molecular probe-based imaging technology, can be successfully integrated to detect
premalignant lesions. We also aimed to evaluate whether the cathepsin B activated NIRF probe
(Prosense™ 680) can differentiate premalignant from benign polyps and inflammatory lesions.
To this end, we compared activation of Prosense™ 680 by adenomatous polyps, hyperplastic
and lymphoid polyps, and acute and chronic inflammatory lesions collected from several
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A protocol for animal use in this study was approved by the University of North Carolina
(UNC) Institutional Animal Care and Use Committee. Mice carrying an inactivating Min
mutation in the adenomatous polyposis coli (Apc) gene (ApcMin/+ mice) were used as a well
characterized model of premalignant adenomatous colonic polyps. ApcMin/+ mice on a C57BL6
background18 and normal wild type (WT) littermates were purchased from Jackson
laboratories and expanded in our facility. For benign lesions we used a SOCS2-HT/GH-TG
mouse model of combined heterozygous disruption of one allele encoding suppressor of
cytokine signaling-2 (SOCS2-HT) and expression of a growth hormone (GH) transgene (GH-
TG), or GH-TG mice that express the GH transgene but have both SOCS2 alleles intact. We
recently showed that SOCS2-HT/GH-TG, and to a lesser extent GH-TG mice develop
spontaneous lymphoid and hyperplastic polyps in the colon which are considered benign
lesions with limited potential for progression to adenoma or adenocarcinoma15. Derivation and
characterization of SOCS2-HT/GH-TG and GH-TG mice on a C57BL6 background were
described recently15. We used wild type (WT) mice treated with sodium dextran sulfate (DSS)
as a model of mucosal injury and acute inflammation mediated primarily by macrophages and
neutrophils16. WT mice on the C57BL6 background were given 3% (wt/vol) dextran sulfate
sodium (DSS; mol wt, 34,000–45,000) in the drinking water for 5 days19. The mice were
subsequently sacrificed on day 3 and day 10 after the end of DSS treatment, times when we,
and others have established that the mice show acute inflammation16. We used mice
homozygous for disruption of both interleukin-10 alleles (interleukin 10 null or IL-10-/-) as a
model of chronic T cell mediated transmural inflammation that can be accompanied by colitis
associated dysplasia or neoplasia17. IL-10-/- mice on a 129SVEv background raised under
specific pathogen free conditions were derived from colonies maintained at UNC. The
genotypes of all mouse models were confirmed by PCR on DNA isolated from tail clips. Mice
were studied between 180 and 240 days of age, times when disease is reliably manifested in
all models.
Probe administration, tissue collection, positive and negative controls
Mice were given a cathepsin B activatable probe (Prosense™ 680; VisEN Medical Inc,
Woburn, MA), intravenously via tail vein injection at a dose of 2nmol/25 gm wt per animal.
Animals were anesthetized and sacrificed 18 hours later and the entire intestine was dissected.
The intestine was opened longitudinally and kept moist with phosphate buffered saline and
imaged immediately under white light or NIRF. The intestine was subsequently fixed in
formalin for 24 hours and preserved in 70% ethanol. Uninjected animals were used as controls.
Prosense™ 680 samples added to buffer with and without trypsin, a protease capable of probe
activation, served as positive and negative controls. Prosense™ 680 was activated within ten
minutes at ambient temperature upon mixing of 10μl 10μM Prosense™ 680, 20μl 5% trypsin
(Sigma-Aldrich, St. Louis, MO), and 70μl phosphate buffered saline (PBS). Different
concentrations were prepared by serial dilution in PBS.
White Light and NIRF Imaging using CE or conventional imaging
A dedicated light tight imaging chamber was constructed to permit CE based imaging under
white light or NIRF (Fig. 1). CE movement through the intestine was simulated with a
motorized linear platform mounted with the dissected tissue of interest. The platform and
attached tissue were moved at uniform speed across the CE using a stepper motor controlled
by a desktop computer running Matlab utilizing a National Instruments USB-6008 data
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acquisition device. The CE to tissue distance was constant at 4 cm. Images acquired were
transmitted to a recorder via sensor arrays fastened to the outside of the light-tight chamber.
Data collected inside the recorder was then downloaded and reviewed in standard fashion. For
white light imaging, a CE was suspended above the platform inside the imaging chamber,
allowing images of the objects placed on the moving platform to be captured (Fig 1). For NIRF
imaging, a similar assembly was used except that an external LED light source was used and
a three-component filter set was placed between the tissue and CE (Fig 2). This filter set
represents a near-infrared filtering device consisting of excitation (680 nm), dichroic, and
emission (700 nm) filters. These filters were situated so that the excitation filter was adjacent
to the LED and vertical to the platform. The dichroic filter was 45 degrees to the platform
diverting 680 nm light to the tissue, the appropriate wavelength to activate the probe. Activated
probe emitted light at 700 nm which can pass through the dichroic filter and the emission filter
which was horizontal to the platform and placed immediately in front of the CE. In the NIRF
imaging experiments with modified CE, samples were laid out in order from left to right as
follows: positive control with activated Prosense™ 680 (AP), negative control with inactive
Prosense™ 680 (IP), negative control tissue from uninjected animals (NT), and adenomatous
polyps (Ad) dissected from colon of ApcMin/+ mice (Fig 5, top panel). Correlation was made
between the white light and NIRF images by image comparison and by measuring the time
elapsed between visualization of the positive control and tissue of interest under white light
versus NIRF.
To confirm data obtained with CE and in experiments to test whether Prosense™ 680
discriminated premalignant from hyperplastic or lymphoid polpys, or from acute or chronic
inflammation, imaging of samples was also performed with the Xenogen IVIS Imaging System
200 Series and Cy5.5 fluorescent filter set.
RESULTS
NIRF Integrated CE Detects Different Intensity NIRF Signals
Activated Prosense™ 680 (AP) was obtained by mixing 10ml 10mM Prosense™ 680 and 20ml
5% trypsin in 70ml phosphate buffered saline (PBS pH 7.4) at room temperature. Different
concentrations were achieved by 1:5 and 1:10 dilution in PBS. The NIRF integrated CE was
capable of detecting NIRF signal intensity across this 10 fold probe concentration difference
(Fig 3). This provided initial proof of principle that the modified CE system can detect NIRF.
Detection of Adenomatous Polyps in ApcMin/+ Mice by Modified CE
A white light image of a segment of Prosense™ 680 injected ApcMin/+ mouse colon containing
two adenomatous polyps captured by a conventional CE is shown in Fig 4. The quality of the
white-light images obtained using CE in the imaging chamber was excellent. Imaging of the
same intestinal segment and polyps with the modified CE detected clear NIRF signals (solid
arrows, Fig 5 bottom panels). As expected, NIRF signal was also detected from the positive
control (block arrow, Fig 5 bottom panels), but not from the negative controls. Successful NIRF
imaging of the adenomas was further confirmed with positioning coordinates from the time
record. Using the layout of samples illustrated in the top panel of Fig 5, the time elapsed
between NIRF visualization of the activated Prosense™ 680 positive control and visualization
of the two adenomatous polyps from the injected ApcMin/+ mouse (1 minute 18 seconds, Fig
5 bottom panels) was virtually identical to the time elapsed between visualization of these
samples under white light (1 minute 16 seconds, Fig 5 middle panels). This provides objective
evidence that NIRF signals were indeed emitted from the polyps of Prosense™ 680 injected
ApcMin/+ mouse.
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A circular reflection generated by the CE LEDs above the emission filter was visible in the
center of the NIRF images. This reflection did not interfere with the visualization of NIRF
signals.
In addition to the rounded NIRF signals corresponding to positive control and polyps visualized
at the center of the CE viewing field, additional NIRF signals were detected which were artifact
from reflection of the external dichroic filter. These signals could easily be distinguished from
true NIRF signals and did not confound interpretations when images were viewed as a video.
(Video clips are available as supplemental data.)
NIRF Imaging of Murine Colonic Lymphoid and Hyperplastic Polyps
No NIRF signals were detected from the polypoid, non-adenomatous lesions of the large
intestines of Prosense™ 680 injected SOCS2-HT/GH-TG and GH-TG mice by the modified
CE (data not shown). Further verification of this finding was carried out by Xenogen IVIS
system (Fig 6). The visible polypoid lesions seen in the large intestines of SOCS2-HT/GH-
TG and GH-TG mice were dissected individually and imaged on the same slide with
adenomatous polyps from injected ApcMin/+ mouse and samples of trypsin-activated
Prosense™ 680 as positive controls. Only background NIRF signals were detected from these
polypoid lesions, while ApcMin/+ adenomas and activated protease controls yielded strong
signals. These polypoid lesions from SOCS2-HT/GH-TG and GH-TG mice were confirmed to
be either lymphoid aggregates or hyperplastic polyps in all cases by histological examination
of H&E stained sections of the polyps.
NIRF Imaging of Acute and Chronic Inflammation of Murine Intestines
NIRF signals were not detected using the modified CE in the colon of DSS-treated WT mice
or in small intestine or colon of IL-10-/- mice (data not shown). Consistent with these findings
NIRF images from Xenogen IVIS system showed minimal activation of Prosense™ 680 in the
colon of DSS treated mice when referenced with adenomatous polyps from Prosense™ 680
injected ApcMin/+ mouse and positive control with activated Prosense™ 680 (Fig 7). Similarly,
the duodenum, ileum and colon of IL-10-/- mice yielded minimal activation of probe. It is
established that colon and cecum are major sites of chronic inflammation in the IL-10-/- model,
and that duodenum can also be involved in older mice as studied here14. Intriguingly, the cecum
of the IL-10-/- mice yielded minor background NIRF except for a strong signal in a lesion
confirmed as a cecal adenoma (Cecal Ad, Fig 7) on histology This underscores the capability
of the probe and modified CE to localize premalignant lesions within a background of chronic
inflammation14.
DISCUSSION
We have demonstrated proof of principle for biochromoendoscopy by integrating “molecular
beacons” with NIRF imaging and conventional CE. Our modified CE was capable of detecting
NIRF signals emitted from adenomatous polyps in intestines of ApcMin/+ mice injected with a
cathepsin B activatable probe. Importantly, such NIRF signals were specific to the
precancerous adenomatous polyps. Benign growths such as hyperplastic polyps or lymphoid
aggregates found in similarly treated SOCS2-HT/GH-TG or GH-TG mice did not emit NIRF
signals. In addition, NIRF signals were not observed in inflamed intestine of the DSS acute
inflammation model or the IL-10-/- chronic inflammation model. Nonetheless, the cathepsin B
activated probe did detect an adenoma in the cecum with chronic inflammation of the IL-10
null mouse model. Together, these findings indicate that the added functionality of the
molecular probe combined with CE has the potential to distinguish different types of lesions
throughout the GI tract. Future application of biochromoendoscopy in human subjects could
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circumvent the diagnostic limitations of existing CE and the invasiveness of conventional
endoscopy.
Our results with different doses of activated probe demonstrate that it is possible to detect NIRF
signals varying by an order of magnitude. The ability of the integrated CE to detect a difference
in NIRF signal intensity is significant since it offers quantification potential. Biomarker-
specific signal intensity may reflect the severity of underlying disease processes and may allow
a more accurate measurement of the severity or stage of disease process in different subjects.
Our current studies used preselected lesions of different types to obtain proof of principle that
biochromoendoscopy can be applied to discriminate lesions with differing malignant potential.
Future studies could employ the elegant quantitative methods reported by Marten and
colleagues9, and use CE combined with NIRF to quantify the mean signal intensities and target
to background ratio obtained with NIRF probes such as cathepsin B activated Prosense™ 680,
or other molecular probes, in our well-characterized mouse models. This would provide
quantitative data about the sensitivity and discriminating capabilities of biochromoendoscopy
using CE and different molecular probes. Such studies will be best undertaken after further
refining of the NIRF integrated CE system.
The quality of the NIRF images from our modified CE integrated with molecular probe is
acceptable to show proof of principle, but further improvement can be achieved by reducing
the signal artifact of the modified CE. One limitation resulted from the external placement of
the filter setup in our prototype, which necessarily meant that tissues were placed at a minimum
of 4cm from the CE and external filters. Conventional CE visualizes lesions at close proximity.
Various modified CE design options would facilitate direct and close proximity NIRF imaging
by CE, to enhance the sensitivity and resolution of the system. For example, the NIRF imaging
device can be easily assembled by attaching a round planar filter in front of the lens and
illuminating LEDs. This round planar filter would be constructed with a center core emission
filter surrounded by an outer donut-shaped excitation filter in proximity to the illuminating
LEDs (A, Fig 8). This simpler design would eliminate the need for a dichroic filter, solve signal
artifact and reflection problems, and enhance the resolution of NIRF images.
Biochromoendoscopy with integrated CE and molecular imaging could be potentially
incorporated into screening programs for colon cancer. Recent studies report that white light
CE shows promise in the detection of colonic adenomas compared with conventional fiberoptic
colonoscopy20, 21. Our results suggest that modified CE may further enhance the ability to
detect and characterize colonic adenomas by visualizing the same lesion under both standard
white light image and NIRF image. This may be accomplished, for example, with a modified
twin camera capsule (Fig 8), which would be similar to the commercially available esophageal
capsule. In addition, because of the specificity of NIRF signals for adenomatous polyps as
demonstrated in our study, different types of lesion in the colon could be differentiated by
probes activated by specific biomarkers on distinct lesion types, a task difficult to achieve by
non-invasive white light based CE. Similarly, biochromoendoscopy has a potentially important
role in gastric cancer screening programs in some areas of the world, if the gastric capsule
endoscopy is developed and combined with appropriate molecular probes.
Lastly, although we have focused on the use of modified CE with molecular probes for
minimally invasive detection and differentiation of premalignant from benign and
inflammatory gastrointestinal lesions, this novel approach may have broader applications
throughout the GI tract. As more NIRF or other imaging probes for different disease processes
are developed22, 23, this technology could potentially allow the detection and differentiation
of inflammatory diseases such as Crohn’s disease and malignant infiltrative processes such as
lymphoma. Biochromoendoscopy may be useful to distinguish inflammatory lesions such as
ulcerations caused by Crohn’s disease from those induced by medications (e.g. NSAIDs). We
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speculate that it may also be useful to identify particular microorganisms in the GI tract if
imaging probes specific for the organism are available. The ability to differentiate these very
different disease processes in a non-invasive fashion would be invaluable in medical decision
making. Lastly, as well as being less invasive than conventional endoscopy,
biochromoendoscopy is less resource dependent and could be utilized in populations with
limited endoscopy resources.
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Figure 1. Light-tight chamber setup for white light imaging
Apparatus includes a moving platform controlled by a stepper motor (A), conventional CE (B)
suspended above the platform, and data analysis system (C).
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Figure 2. Light-tight chamber setup for NIRF imaging
Similar setup as in white light imaging (A – C) except for an external LED light source (D)
and a filter set (E) suspended in between VCE and platform. The filter set consists of three
filters: excitation filter (680 nm) vertical to the platform, dichroic filter at 45 degrees, and
emission filter (700 nm) horizontal to the platform.
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Figure 3. NIRF imaging of activated Prosense™ 680 at different concentrations
NIRF images of different dilutions of activated Prosense™ 680 over a ten fold concentration
difference collected by modified CE. Note the progressive decrease in signal intensity with
decreasing concentrations of activated probe.
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Figure 4. CE based white light imaging of adenomatous polyps through custom built light-tight
chamber
White light image by conventional CE of a segment of ApcMin/+ mouse colon containing two
polyps (arrows).
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Top Panel: Sample layout during typical white light and NIRF imaging with CE (top
panel). Schematic illustration of sample layout in the order from left to right: AP = activated
Prosense™ 680 as positive control; IP = negative inactive Prosense™ 680 as negative control;
3) NT= negative tissue control from uninjected animals; Ad = adenomatous polyps dissected
from ApcMin/+ mouse colon. Middle and Bottom Panels: CE based white light and NIRF
images of activated probe (AP) and two adenomatous polyps (Ad). The four panels show
first the visualization of the activated probe (AP, block arrow) followed by images of two
adenomatous polyps as they move into the view of the CE with polyp 1 visualized first (single
solid arrow), both polyps 1 & 2 (double solid arrow) and then only polyp 2 (single solid arrow).
The time when the AP probe is first visible serves as a reference for other frames which show
images of the polyps under white light or NIRF. Note that the time elapsed between
visualization of AP and visualization of polyps is almost identical with white light and NIRF
imaging.
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Figure 6. NIRF imaging of lymphoid polyps (LP) and hyperplastic polyps (HP)
NIRF images collected by a Xenogen IVIS system of dissected colonic lymphoid polyps (LP)
and hyperplastic polyps (HP) from mouse NB300, a SOCS2-HT/GH-TG (Right) and mice
NB287 and NB294, which were GH-TG (left). Note the isolated lymphoid and hyperplastic
polyps had no NIRF signal. Activated Prosense™ 680 (AP) and adenomatous polyps (Ad)
from Prosense™ 680 injected ApcMin/+ mouse colon imaged under identical conditions served
as positive controls.
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Figure 7. NIRF imaging of acute and chronic intestinal inflammation
NIRF images captured by a Xenogen IVIS system of: Right = colon of DSS treated WT mice
sacrificed 3 (DSS+3) or 10 days (DSS+10) after DSS treatment. Left = NIRF images of
duodenum, ileum, colon and cecum of an IL-10-/- mouse. Note background signals except for
what proved to be a cecal adenoma (Cecal Ad). The inflamed colon had no NIRF signals.
Activated Prosense™ 680 (AP) served as positive control.
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Figure 8. Proposed design of integrated VCE with molecular imaging capability
Conversion of one of the twin camera CE into a NIRF imaging device by attaching a round
planar filter to camera A, in front of the lens and illuminating LEDs. This round planar filter
will be woven so that the center core covering the lens contains the emission filter and the outer
donut-shaped rim covering the illuminating LEDs contains the excitation filter. The white light
camera B of the CE remains intact at the other end of the capsule.
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